AstraZeneca (NYSE: AZN) today announced it has completed patient enrollment approximately four months ahead of plan in the Phase III clinical trial EUCLID studying BRILINTA(r) (ticagrelor) tablets. Part of PARTHENON, AstraZeneca's largest clinical trial program, EUCLID has randomized more than 13,500 patients globally with peripheral artery disease (PAD); approximately 20 percent are patients in the United States (US) from more than 300 active clinical trial sites across the country. EUCLID is designed to evaluate the effects of ticagrelor (monotherapy) compared to clopidogrel (monotherapy) on cardiovascular (CV) events and safety in PAD patients. Ticagrelor is currently not approved for the treatment of patients with PAD.

Texas Heart Institute doctors at CHI St. Luke's Health Baylor St. Luke's Medical Center, are the first in Texas to have implanted a device designed to seal abdominal aortic aneurysms (AAAs), rather than bridging through the aneurysms using a traditional stent.

Researchers at the University of Colorado Denver | Anschutz Medical Campus, already focused on understanding and minimizing the effects of stroke in children, will receive $3 million as part of a national effort to better understand stroke.

A University of Illinois at Chicago researcher will test whether brain stimulation combined with gait training can improve patients’ ability to walk after a stroke, under a $1.5 million grant from the National Institute of Child Health and Human Development.

AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) cleared an expanded indication for its AngioVac cannula for venous drainage during extracorporeal bypass for up to six hours to include removal of fresh, soft thrombi or emboli.

Cardiovascular Systems, Inc. (NASDAQ: CSII) (CSI), announced today it has received FDA clearance of its new Diamondback 360®60cm Peripheral Orbital Atherectomy Systems (OAS) for the treatment of peripheral arterial disease (PAD).

Cordis Corporation announced today that it has received European CE Mark for its RENLANE™ Renal Denervation System for the treatment of patients with resistant hypertension and has completed the first successful cases in Europe. The RENLANE™ System consists of a unique, helical shaped, irrigated, multi-electrode ablation catheter with a multi-channel radiofrequency (RF) ablation system.

Aligned with its commitment to provide innovative medical technology for the interventional treatment of peripheral artery disease, Medtronic, Inc. (NYSE: MDT) has initiated the European launch of the TOTAL across crossing catheter, which recently received the CE (Conformité Européene) mark as a tool for improving blood flow through narrowed or occluded lower-extremity arteries, including those in the especially challenging below-the-knee (BTK) vessel bed.